Guilford’s Gliadel Wafer
This article was originally published in The Gray Sheet
Recent Phase III long-term survival results for the Gliadel Wafer should reverse a non-approvable decision by FDA on a supplemental new drug application, Guilford claims. A March 2002 non-approvable letter from CMS stated the 23% reduction in risk of death with the primary brain cancer treatment was not statistically significant (1"The Gray Sheet" March 25, 2002, p. 12). Recent results show the device reduces the risk of death by 27% over three to four years...
You may also be interested in...
Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's "non-approvable" letter for newly diagnosed malignant glioma
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.